Herein, with the aim of enriching prognostic markers of ASXL1mt, we conducted a retrospective study to analyze the prognosis and risk factors for ASXL1mt in patients with AML and MDS, including age, sex, risk stratification, fusion gene, karyotype, co‐mutations of high frequencies, variant allele frequency (VAF), and mutation site of ASXL1. This evidence concerns the gene ASXL1 and acute myeloid leukemia.